One PrEP Regimen Linked to Higher Risk of Hypertension, Statin Use Over Another
Use of tenofovir alafenamide fumarate (TAF) for HIV pre-exposure prophylaxis (PrEP) was associated with an increased risk of hypertension and the initiation of statin use within 2 years compared with the use of tenofovir disoproxil fumarate (TDF; Viread), especially for people over age 40, a retrospective cohort study found. In a cohort of patients without […]